Role of novel kidney injury biomarkers in perioperative acute kidney injury

Chirag Parikh, William R. Zhang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.

Original languageEnglish (US)
Title of host publicationPerioperative Kidney Injury
Subtitle of host publicationPrinciples of Risk Assessment, Diagnosis and Treatment
PublisherSpringer New York
Pages25-36
Number of pages12
ISBN (Electronic)9781493912735
ISBN (Print)9781493912728
DOIs
StatePublished - Jan 1 2015

Fingerprint

Acute Kidney Injury
Biomarkers
Kidney
Wounds and Injuries
Cystatin C
Fatty Acid-Binding Proteins
Interleukin-18
Disease Management
Protein C
Creatinine
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parikh, C., & Zhang, W. R. (2015). Role of novel kidney injury biomarkers in perioperative acute kidney injury. In Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment (pp. 25-36). Springer New York. https://doi.org/10.1007/978-1-4939-1273-5_3

Role of novel kidney injury biomarkers in perioperative acute kidney injury. / Parikh, Chirag; Zhang, William R.

Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment. Springer New York, 2015. p. 25-36.

Research output: Chapter in Book/Report/Conference proceedingChapter

Parikh, C & Zhang, WR 2015, Role of novel kidney injury biomarkers in perioperative acute kidney injury. in Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment. Springer New York, pp. 25-36. https://doi.org/10.1007/978-1-4939-1273-5_3
Parikh C, Zhang WR. Role of novel kidney injury biomarkers in perioperative acute kidney injury. In Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment. Springer New York. 2015. p. 25-36 https://doi.org/10.1007/978-1-4939-1273-5_3
Parikh, Chirag ; Zhang, William R. / Role of novel kidney injury biomarkers in perioperative acute kidney injury. Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment. Springer New York, 2015. pp. 25-36
@inbook{31843080028b4823a2a7fdba05260766,
title = "Role of novel kidney injury biomarkers in perioperative acute kidney injury",
abstract = "The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.",
author = "Chirag Parikh and Zhang, {William R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1273-5_3",
language = "English (US)",
isbn = "9781493912728",
pages = "25--36",
booktitle = "Perioperative Kidney Injury",
publisher = "Springer New York",

}

TY - CHAP

T1 - Role of novel kidney injury biomarkers in perioperative acute kidney injury

AU - Parikh, Chirag

AU - Zhang, William R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.

AB - The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.

UR - http://www.scopus.com/inward/record.url?scp=84944073344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944073344&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1273-5_3

DO - 10.1007/978-1-4939-1273-5_3

M3 - Chapter

AN - SCOPUS:84944073344

SN - 9781493912728

SP - 25

EP - 36

BT - Perioperative Kidney Injury

PB - Springer New York

ER -